Invention Grant
US09580504B1 Pidilizumab monoclonal antibody therapy following stem cell transplantation
有权
Pidilizumab单克隆抗体治疗干细胞移植后
- Patent Title: Pidilizumab monoclonal antibody therapy following stem cell transplantation
- Patent Title (中): Pidilizumab单克隆抗体治疗干细胞移植后
-
Application No.: US14536343Application Date: 2014-11-07
-
Publication No.: US09580504B1Publication Date: 2017-02-28
- Inventor: Rinat Rotem-Yehudar , Michael Schickler
- Applicant: CureTech Ltd.
- Applicant Address: IL Yavne
- Assignee: CureTech Ltd.
- Current Assignee: CureTech Ltd.
- Current Assignee Address: IL Yavne
- Agency: Winston & Strawn LLP
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395
Abstract:
Methods for treating specific populations of cancer patients, specifically patients suffering from cancer who undergo stem cell transplantation and were classified as positive by a pre-transplant metabolic imaging, by administering to the subject a therapeutically effective amount of a pidilizumab monoclonal antibody.
Information query
